ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

LAMPRENE
Bacterial infections
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

LAMPRENE Rx

Generic Name and Formulations:
Clofazimine 50mg; soft gel caps.

Company:
Novartis Pharmaceuticals Corp

Therapeutic Use:

Indications for LAMPRENE:

Lepromatous leprosy, including dapsone-resistant, and/or complicated by erythema nodosum leprosum.

Adult:

Take with meals. Dapsone-sensitive: 100mg daily with 2 other antileprosy drugs for ≥2 years until skin smears negative, then use antileprosy monotherapy. Dapsone-resistant: 100mg daily with ≥1 other antileprosy drug for 3 years, then 100mg daily as monotherapy. Erythema nodosum: 100–200mg daily in combination with baseline antileprosy treatment and steroids as clinically indicated; if administered at 200mg dose, taper to 100mg as soon as possible; see full labeling.

Children:

Not established.

Warnings/Precautions:

Abdominal obstruction and other GI disorders (eg, abdominal pain, nausea, vomiting, diarrhea); if occurs, consider reducing dose, increasing dosing interval, or discontinuing. QT prolongation: monitor ECGs. Psychological effects of skin discoloration: monitor for depression or suicidal ideation. Elderly. Pregnancy; verify status prior to initiation. Females of reproductive potential should use effective contraception and males (condoms) during treatment and for at least 4 months after completion. Nursing mothers: not recommended.

Interactions:

Dapsone may inhibit antiinflammatory activity. Concomitant with other QT prolonging drugs or with bedaquiline may cause additive QT prolongation.

Pharmacological Class:

Antileprosy.

Adverse Reactions:

Skin and body fluid discoloration (conjunctivae, tears, urine, fecal, sputum, or sweat), ichthyosis, dryness, rash, pruritus, diarrhea, nausea, vomiting, GI intolerance, abdominal/epigastric pain; elevated blood glucose or ESR; QT prolongation, Torsades de Pointes.

How Supplied:

Caps—100

Sign Up for Free e-newsletters